Development and Regulatory status
Phase III Clinical Trials
An oral multi-kinase inhibitor that potently blocks multiple protein kinases involved in tumour angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), metastasis (VEGFR3, PDGFR, FGFR) and tumour immunity (CSF1R) .
Glioblastomas are the most common type of primary brain tumour in adults and account for 12-15% of all brain tumours. However, with about 3 to 4 new cases of glioblastoma diagnosed each year per 100,000 people in the UK, glioblastoma is still classed as a rare cancer. Glioblastoma primarily affects adults between 45 and 75 years old and it is slightly more common in men than in women .